We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

1 hedge funds and large institutions have $0 invested in Statera Biopharma, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

100% less capital invested

Capital invested by funds: $1 → $0 (-$1)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

STAB Hedge Fund Activity: Q3 2024 in Review

1 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2024, worth a combined $0 — down 100% from $1 a quarter earlier.

Fund positioning in STAB was balanced in Q3 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $0 of Statera Biopharma, Inc. Common Stock stock for Q3 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2024 and 0 closed out.

Based on aggregated 13F filings for Q3 2024.